LC
ADMA icon

Lindbrook Capital’s ADMA Biologics ADMA Stock Holding History

Lindbrook Capital’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$10.1K Buy
508
+178
+54% +$3.08K ﹤0.01% 1648
2024
Q4 		$5.66K Sell
330
-72
-18% -$1.35K ﹤0.01% 1928
2024
Q3 		$8.04K Buy
402
+162
+68% +$2.52K ﹤0.01% 1797
2024
Q2 		$2.68K Buy
+240
New +$2.01K ﹤0.01% 2253

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

Lindbrook Capital's ADMA Position: Q1 2025 in Review

Lindbrook Capital increased its ADMA Biologics (ADMA) stake by 54% in Q1 2025, buying an estimated $3.08K and bringing the position to 508 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1648.

Lindbrook Capital first reported a position in ADMA in Q2 2024 and has held it in 4 quarters since. 346 funds tracked by Wall St. Rank hold ADMA as of Q1 2025.

  • Lindbrook Capital held 508 shares of ADMA Biologics worth $10.1K as of Q1 2025.
  • Lindbrook Capital bought 178 ADMA Biologics shares in Q1 2025, an estimated $3.08K.
  • ADMA Biologics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1648 holding.
  • Lindbrook Capital first reported a position in ADMA Biologics in Q2 2024 and has held it in 4 quarters since.
  • 346 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.